Posted by Michael Wonder on 21 Dec 2020
PHARMAC to fund new diabetes medicines with amended Special Authority criteria
21 December 2020 - PHARMAC has approved funding for two new medicines with substantial health benefits for around 53,000 New Zealanders with type 2 diabetes mellitus.
People with high risk type 2 diabetes mellitus, who meet the funding criteria, will be able to access funded empagliflozin (with or without metformin) from 1 February 2021.
They will also be able to get funded dulaglutide once it has Medsafe approval.
